Protagen develops powerful precision diagnostic tools to support drug development, facilitate better treatment strategies and improve patient management in the areas of immuno-oncology and autoimmune disease.
Why do some cancer and autoimmune disease patients respond well to their treatments, whilst others do not?
Why do some patients that undergo immunotherapies for their cancer develop debilitating and sometimes-harmful immune-related Adverse Events (irAEs)?
Are we able to develop tools that will allow us to predict the response of cancer immunotherapies or autoimmune disease treatments?
Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibodies as effective biomarkers for autoimmune disease and immuno-oncology, and is developing tools that will allow us to answer these questions.
By continuing to apply its biomarker discovery platform, SeroTag®, and its portfolio of NavigAID patient stratification products, Protagen is able to identify valuable biomarkers that support pharmaceutical development, personalized treatment regimens and improve patient management.
Contact us to find out more.
How we got here
Founded in 1997, Protagen began life as a protein analysis services company—a spin-out from the Ruhr-University of Bochum. In 2011, Protagen strengthened its protein library and biomarker discovery capabilities, by utilizing the power of autoantibodies. The company’s experience and expertise in autoantibody serum screening and biomarker development has continued to push Protagen forward, leading to the establishment of the SeroTag® process.
Protagen has continued to garner market reputation and established itself as a provider of precision medicine tools for autoimmune diseases. The company has worked with most of the top 10 global pharmaceutical companies—utilizing its NavigAID patient stratification products to answer their most pressing questions—and has brought its IVD expertise to the field of autoimmune disease.
In 2017, Protagen utilized its expertise with analyzing and working with autoantibodies to focus on the field of immuno-oncology, where it initiated a number of strategic collaborations with world-leading institutes such as the National Center for Tumor Diseases (NCT) in Germany, the National Cancer Institute (NCI) in the USA, Gustave Roussy (GR) in France and the University of California, San Francisco (UCSF). Protagen’s work in this filed has helped identify autoantibodies as biomarkers for predicting and monitoring the incidence of immune-related adverse events (irAEs), as well as therapeutic outcomes for patients undergoing cancer immunotherapy.
The company is continuing to develop approaches that will aid in the successful immuno-profiling of patients suffering from cancer or autoimmune disease, via its own internal research and collaborations with its partners.
Protagen’s corporate leadership team combines over 40 years of commercial expertise and experience within the biotechnology industry, with a background spanning immunology, oncology, biomarker discovery and more.
Protagen is currently setting up an international scientific advisory board with key opinion leaders from the immuno-oncology and autoimmune disease fields. These expert panels will support our efforts in engaging with the medical and scientific community to develop products that are aimed at market needs.
Protagen has a number of established and committed investors, but is always looking at entering into new partnerships to help progress its research and commercialization efforts. If you are interested in investing in the company, please contact us.
Here you will find our quarterly newsletter, “Stratified News from Dortmund”. With our newsletter we intend to regularly update you on developments at Protagen in a fresh and colorful format and we hope that you like it.
Get in touch
Improving the treatment of cancer and autoimmune disease is our passion, and we always welcome the chance to discuss these topics with current and prospective customers, patients and clinicians alike.